Oxford BioMedica PLC (OXBDF)

[marcusl2]

Novartis is clearly looking like it will be the big winner. No one else has followed CAR-treated leukemic patients and their persistently circulating, transgenic T lymphocytes for as long as Professor Carl June's team which has published results on patients followed beyond 5 years. As of May 2016 Professor June claimed to have treated 224 patients. DNA fingerprinting methods revealed that the CAR T cells were still on patrol in small but sufficient numbers to watch for re-emergence of cancer cells. No one has that kind of followup data and published it. No company other than Novartis has the in-house manufacturing expertise and has scaled it for global distribution.
HTTPS://seekingalpha.com/article/4061124-juno-can-car-ts-big-loser-still-worth-2_5b

They assume 4% royalties on ctl019
http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/31.03.17-delivering-commercial-gene-therapy-vector.pdf
We estimate that Novartis will achieve sales of $2.05bn per annum from CTL-019 by 2025. OXB could, therefore, receive a total of $82.0m in royalties per annum, in addition to manufacturing revenue.